Direct-to-Consumer Genetic Testing: Global Markets and Technologies
The global DTC genetic testing market should grow from $1.2 billion in 2020 to $2.7 billion by 2025 with a compound annual growth rate (CAGR) of 17.7% for the period of 2020-2025.
- 12 data tables and 39 additional tables
- An overview of the global markets and technologies for direct to consumer (DTC) genetic testing
- Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Information on key genomic regions associated with genetic testing and description of instruments and technologies used for DTC genetic testing
- Coverage of DNA sequencing; microarray; and software industries and description of the key initiatives in the genetic testing industry
- Detailed analysis of the current market trends, market forecast and discussion of technological, regulatory and competitive elements as well as economic trends affecting the future marketplace for direct to consumer (DTC) genetic testing and impact analysis of COVID-19 on the market
- Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry
- Profiles of the key companies in the DTC testing industry, including Chendu 23Mofang Biotechnology Co. Ltd (23Mofand), Genetic Technologies Ltd, Illumina Inc., Myriad Genetics Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Inc.
The scope of the report includes DTC genetic testing technologies, applications, industry subsegments, major strategic alliances, patents and companies. The market sizes for next generation cancer diagnostics are given for 2019, 2020 (estimated) and 2025 (forecasted).
This report reviews the main DTC genetic testing technologies, including next-generation sequencing (NGS), polymerase chain reaction (PCR) and genotyping microarrays.
The report then discusses several of the significant large-scale population sequencing initiatives that are contributing to DTC genetic testing development. Key forces driving the market are enumerated.
The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2019 through September 2020. Industry subsectors analyzed include ancestry, clinical health, recreational health, sequencing data-based blockchain, sequencing instrument, long-read sequencing, sequencing informatics and PCR.
The market for DTC genetic testing is analyzed in depth. The market is analyzed by test purpose (ancestry, health, lifestyle); by technology platform (PCR, genotyping arrays, sequencing); by delivery format (test kits, virtual tests); and by geography (North America, Europe, Asia/Pacific, RoW).
The ancestry market segment is analyzed by technology and by ethnicity (African, Asian, European, Latino, other). The health market segment is analyzed by technology and by disease category (cancer, cardiovascular, complex common, pharmacogenomics, rare diseases and other). The lifestyle market segment is analyzed by technology and by application (genetic relatedness, nutrigenomics, personal traits, weight management/fitness, other)
Market data covers 2019, 2020 (estimated) and 2025 (forecasted).
More than 55 companies in the DTC genetic testing industry are profiled in this report.
BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2019 through September 2020, including key alliance trends.
John Bergin has produced successful and highly regarded market research reports in the life science industry for BCC research for more than 10 years. Mr. Bergin has held business development and international sales and marketing positions with Corning Inc., an advanced materials company. He has also held executive management positions with IBC Advanced Technologies, a molecular recognition company specializing in separations. Mr. Bergin's extensive expertise in commercializing new technologies is reflected in his market research reports.
Mr. Bergin received a BS degree in Chemistry and Masters of Business Administration (MBA) degree from Brigham Young University and an MS degree in biotechnology from Johns Hopkins University. John Bergin is a pseudonym of the author.